NYSE:PFEPharmaceuticals
Pfizer’s ELREXFIO Data Reshapes Multiple Myeloma Outlook And Revenue Story
Pfizer (NYSE:PFE) reported positive Phase 3 results for ELREXFIO (elranatamab) in the MagnetisMM-5 study in adults with relapsed or refractory multiple myeloma.
The trial met its primary endpoint with a statistically significant and clinically meaningful progression free survival benefit for ELREXFIO as a monotherapy.
The data may support use in broader treatment lines beyond the current later line approval base, subject to regulatory review.
For Pfizer, a large cap pharma group with an...